Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
BioVaxys Expands Cancer Vaccine Platform
BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) (“BioVaxys” or “Company”), announced today the expansion of […]
Ian Fraser Appointed as EVP Clinical Development
Bionical Emas, a global Contract Research Organisation (CRO) providing services to the pharmaceutical and biotech […]
Optellum Attains CE Marking for Its Early Lung Cancer Diagnosis AI Technology
Optellum, an Oxford-based medtech company that provides breakthrough AI technologies to help with early diagnosis of […]
FDA Granted Orphan Drug Designation to CER-001 for the Treatment of LCAT Deficiency
ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to […]
Ad Hoc Announcement Pursuant to Art. 53 Lr Roche Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-stage Small Cell Lung Cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III SKYSCRAPER-02 study, evaluating the […]
NHS Comment On Study Linking Type 2 Diabetes To Earlier Health Problems
Comment from Professor Jonathan Valabhji on a new study from the University of Cambridge, that […]
John Theurer Cancer Center Treats First Patient in U.S. with Investigational New Treatment for Brain Cancer
John Theurer Cancer Center at Hackensack University Medical Center, New Jersey’s top ranked cancer center, according to U.S. […]
XNK Therapeutics Raises SEK 132 Million to Accelerate Growth
XNK Therapeutics AB (“XNK”) today announced it has secured a private placement of SEK 132 million, […]
Novo Nordisk Receives Fda Approval of Higher-dose Ozempic® 2 Mg Providing Increased Glycemic Control for Adults With Type 2 Diabetes
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a […]
Aristea Therapeutics Announces Dosing of First Patient in Phase 2b Trial of RIST4721 in Palmoplantar Pustulosis
Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more